Comparative Pharmacology
Head-to-head clinical analysis: AMIKACIN SULFATE versus GENOPTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKACIN SULFATE versus GENOPTIC.
AMIKACIN SULFATE vs GENOPTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.
Genoptic (gentamicin ophthalmic) is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
15 mg/kg/day IV or IM divided every 8-12 hours; typical adult dose 500 mg IV/IM every 12 hours or 7.5 mg/kg every 12 hours.
Instill 1-2 drops into affected eye(s) every 4-6 hours; for severe infections, every 1-2 hours initially, then reduce frequency as improvement occurs.
None Documented
None Documented
Terminal: 2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; neonates 4-8 hours.
2-3 hours (prolonged in renal impairment to 18-24 hours); in neonates, 3-8 hours.
Renal: >90% unchanged via glomerular filtration. Biliary/fecal: <1%.
Primarily renal (70-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%.
Category D/X
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic